AR045729A1 - Moduladores de lta4h - Google Patents
Moduladores de lta4hInfo
- Publication number
- AR045729A1 AR045729A1 ARP040102682A ARP040102682A AR045729A1 AR 045729 A1 AR045729 A1 AR 045729A1 AR P040102682 A ARP040102682 A AR P040102682A AR P040102682 A ARP040102682 A AR P040102682A AR 045729 A1 AR045729 A1 AR 045729A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- carbon
- heteroatomic
- co2ry
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Materials Engineering (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Structural Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Reivindicación 1: Uso de por lo menos un modulador de LTA4H seleccionado de compuestos de fórmula (1), en los cuales: X se selecciona del grupo formado por NR5, O, y S, donde R5 es uno de H y CH3; Y se selecciona del grupo formado por CH2, y O; Z se selecciona del grupo formado por O y un enlace; W se selecciona del grupo formado por CH2 y CHR1-CH2, donde R1 es uno de H y OH, en el cual el elemento carbono unido a R1 en dicho CHR1-CH2 no está unido directamente al elemento nitrógeno al cual están unido dicho W; R4 se selecciona del grupo formado por H, OCH3, Cl, F, Br, I, OH, NH2, CN, CF3 y CH3; R6 es H o F; y R2 y R3 se seleccionan, cada uno en forma independiente, del grupo formado por: A) es H, alquilo, C1-7, alquenilo C3-7, donde el carbono en dicho alquenilo que está unido al elemento nitrógeno sólo tiene enlaces simples, alquinilo C3-7, donde el carbono en dicho alquinilo que está unido al elemento nitrógeno sólo tiene enlaces simples, cicloalquilo C3-7 benzofusionado en forma opcional, C5-7 cicloalquenilo, -cicloalquil-(C3-7)-alquilo(C1-7), -alquil-(C1-7)cicloalquilo(C3-7) y fenilo, donde cada uno de los sustituyentes A) está sustituido en forma independiente con 0, 1 ó 2 RQ, y cada uno de dichos RQ es un sustituyente en un elemento carbono que es, por lo menos, un elemento carbono eliminado del elemento nitrógeno; B) un sustituyente HetRa; C) -alquil-(C1-7)C(O)Rx, sustituido en forma opcional con CH2RAr o CH2RAr'; D) -alquil-(C2-5)C(O)Rx, donde dos elementos carbono con valencia permitida en el alquilo C2-5 de dicho -alquil-(C2-5)C(O)Rx son parte de un carbociclo C3-6 saturado; E) -alquil-(C2-5)OH donde dos elementos carbono con valencia permitida en el alquilo C2-5 de dicho -alquil(C2-5)OH son parte de un carbociclo C3-6 saturado; F) -alquil-(C0-4)fenilo, donde el fenilo en dicho -alquil-(C0-4)fenilo está fusionado en dos elementos carbono adyacentes en dicho fenilo a Rf, o es benzofusionado; G) -alquil-(C0-4)Ar6, donde Ar6 es un heteroarilo de 6 miembros que tiene un punto de unión en el elemento carbono y que tiene uno o dos elementos heteroatómicos -N=, y está benzofusionado; H) -alquil-(C0-4)Ar5, donde Ar5 es un heteroarilo de 5 miembros, que tiene un elemento heteroatómico seleccionado del grupo formado por O, S, y >NRY, y que tiene 0 o 1 elemento heteroatómico adicional -N=, que contiene en forma opcional dos grupos carbonilo, y está benzofusionado en forma opcional; I) -alquil-(C1-4)Ar5', donde Ar5' es un heteroarilo de 5 miembros que contiene 3 ó 4 elementos nitrógeno, sustituido en forma opcional con RY, y que tiene un sitio de valencia permitida como punto de unión; J) -alquil-(C0-4)Ar6-6, donde Ar6-6 es un fenilo unido a alquilo C0-4 fusionado en sitios de valencia permitida a un heteroarilo de 6 miembros, donde dicho heteroarilo de 6 miembros tiene uno o dos elementos heteroatómicos -N=; K) -alquil-(C0-4)Ar6-5, donde Ar6-5 es un fenilo unido a alquilo C0-4 fusionado en sitios de valencia permitida a un heteroarilo de 5 miembros, dicho heteroarilo de 5 miembros tiene un elemento heteroatómico seleccionado del grupo formado por O, S, y >NRY, y dicho heteroarilo de 5 miembros tiene 0 ó 1 elemento heteroatómico adicional que es -N=; y L) uno de 2-(4-etil-fenoxi)-benzotiazol, 2-(4-etil-fenoxi)-benzooxazol, y 2-(4-etil-fenoxi)-1H-benzoimidazol; M) SO2-alquilo (C1-4); en forma alternativa R2 y R3 se toman junto con el nitrógeno al cual están unidos para formar un anillo heterocíclico que contiene por lo menos un elemento heteroatómico que es dicho nitrógeno de unión, seleccionándose dicho anillo heterocíclico del grupo formado por: i) un anillo heterocíclico de 4-7 miembros HetRb, teniendo dicho anillo heterocíclico de 4-7 miembros HetRb un elemento heteroatómico que es dicho nitrógeno de unión, y está sustituido con 0, 1 ó 2 sustituyentes en los mismos elementos de sustitución u otros diferentes, seleccionándose dichos sustituyentes del grupo formado por -RY, -CN, -C(O)RY, -alquil-(C0-4)CO2RY, -alquil-(C0-4)C(O)CO2RY, -alquil-(C0-4)ORY, -alquil-(C0-4)C(O)NRYRZ, -alquil-(C0-4)NRYC(O)RZ, -C(O)NRZORY, -alquil-(C0-4)NRYC(O)CH2ORY, -alquil-(C0-4)NRYC(O)CH2C(O)RY, -alquil-(C0-4)NRYCO2RY, - alquil-(C0-4)NRYC(O)NRYRZ, -alquil-(C0-4)NRYC(S)NRYRZ, -NRYC(O)CO2RY, -NRYRZ, -alquil-(C0-4)NRWSO2RY, 1,3-dihidro-indol-2-ona-1-ilo, 1,3-dihidro-benzoimidazol-2-ona-1-ilo, tetrazol-5-ilo, 1-RY-1H-tetrazol-5-ilo, RY-triazolilo, 2RY-2H-tetrazol-5-ilo, pirrolidin-2-tion-1-ilo, piperidin-2-tion-1-ilo, -alquil-(C0-4)C(O)N(RY)(SO2RY), -alquil-(C0-4)N(RY)(SO2)NRYRY, -alquil-(C0-4)N(RY)(SO2)NRYCO2RY, halo o un grupo de fórmulas (2); ii) un anillo heterocíclico de 5-7 miembros HetRc, teniendo dicho anillo heterocíclico de 5-7 miembros HetRc un elemento heteroatómico adicional separado de dicho nitrógeno de unión por lo menos por un elemento carbono, seleccionándose dicho elemento heteroatómico adicional del grupo formado por O, S(=O)0-2, y >NRM, teniendo dicho anillo heterocíclico de 5-7 miembros HetRc 0 ó 1 miembro carbonilo, y está sustituido con 0, 1 ó 2 sustituyentes en los mismos elementos de sustitución de carbono u otros diferentes, seleccionándose dichos sustituyentes del grupo formado por -C(O)RY, -CO2RY, -alquil-(C3-4)CO2RY y RZ; iii) uno de imidazolidin-1-ilo, 2-imidazolin-1-ilo, pirazol-1-ilo, imidazol-1-ilo, 2H-tetrazol-2-ilo, 1H-tetrazol-1-ilo, pirrol-1-ilo, 2-pirrolin-1-ilo, y 3-pirrolin-1-ilo, donde cada uno de dichos 2H-tetrazol-2-ilo y 1H-tetrazol-1-ilo está sustituido en el elemento carbono con 0 ó 1 de -alquil-(C0-4)RZ, -alquil-(C0-4)SRY, -alquil-(C0-4)CO2RY, y el sustituyente HetRa; y iv) uno de 1,2,3,4-tetrahidro-quinolin-1-ilo, 1,2,3,4-tetrahidro- isoquinolin-2-ilo, indol-1-ilo, isoindol-2-ilo, indolin-1-ilo, benzoimidazol-1-ilo, 2,8-diaza-espiro[4.5]decan-1-ona-8-ilo, 4-{[(2-ter-butoxicarbonilamino-ciclobutancarbonil)-amino]-metil}-piperidin-1-ilo, 4-{[(2-amino-ciclobutancarbonil)-amino]- metil}-piperidin-1-ilo, 9-il-ter-butil éster del ácido 3,9-diaza-espiro[5.5]undecan-3-carboxílico, 4-oxo-1-fenil-1,3,8-triaza-espiro[4.5]dec-8-ilo y 4-oxo-1,3,8-triaza-espiro[4.5]dec-8-ilo; donde el sustituyente HetRa es un anillo heterocíclico de 4- 7 miembros que tiene un punto de unión en el elemento carbono y que contiene un miembro >NRM como elemento heteroatómico, y dicho elemento heteroatómico está separado de dicho punto de unión al elemento carbono por lo menos por un elemento carbono adicional; RK se selecciona del grupo formado por H, -alquilo C1-4, -alquil-(C0-4)RAr, cada uno sustituido en forma opcional con 1, 2 ó 3 sustituyentes RN; RL se selecciona del grupo formado por -CO2RS y -C(O)NRSRS'; RM se selecciona del grupo formado por RZ, indol-7-ilo, -SO2RY, -alquil-(C3-4)CO2RY, -CO2RY, -C(O)NRZORY, -C(O)RY, -C(O)alquil-(C1-4)ORY, -alquil-(C0-4)C(O)NRSRS', alquil-(C1-4)C(O)CO2RY, 1,3-dihidro-indol-2-ona-1-ilo, 1,3-dihidro-benzoimidazol-2-ona-1-ilo, tetrazol-5-ilo, 1- RY-1H-tetrazol-5-ilo, RY-triazolilo, 2-RY-2H-tetrazol-5-ilo y -alquil-(C0-4)C(O)N(RY)(SO2RY), cada uno sustituido en forma opcional con 1, 2 ó 3 sustituyentes RN; RN se selecciona del grupo formado por OCH3, Cl, F, Br, I, OH, NH2, CN, CF3, CH3, OC(O)CH3, y NO2; RP se selecciona del grupo formado por RY, -alquil-(C2-4)ORY, RAr, -alquil-(C1-2)CO2RY, -alquil-(C1-2)-CONRSRS', indol-7-ilo, y -SO2alquilo(C1-4), RQ se selecciona del grupo formado por fluoro, cloro, bromo, yodo, trifluorometilo, triclorometilo, -CN, -alquilo C1-4, -alquil-(C0-4)RAr, -alquil-(C0-4)RAr', -alquil-(C0-4)ORY, -alquil-(C0-4)CO2RY, -alquil-(C0-4)NRYRZ, -alquil-(C0-4)NRYCORY, -alquil-(C0-4)NRYCONRYRZ, -alquil-(C0-4)NRYSO2RY y -alquil-(C0-4)SRY; RS y RS' se seleccionan en forma independiente del grupo formado por H, -alquilo C1-4, y -alquil-(C0-4)fenilo; en forma alternativa, RS y RS' se toman junto con el elemento nitrógeno al cual dichos RS y RS' están unidos para formar un anillo heterocíclico de 4- 7 miembros que tiene 0 o 1 elemento heteroatómico adicional seleccionado del grupo formado por O, S y >NRY, siempre que dicho elemento heteroatómico adicional esté separado por lo menos por dos elementos carbono de dicho elemento nitrógeno al cual dichos RS y RS' están unidos, y siempre que cuando RY sea alquil-(C0-4)RAr, entonces RAr no esté sustituido con RL; RW se selecciona del grupo formado por RY y -cicloalquilo C3-7; RX se selecciona del grupo formado por -ORY, -NRYRZ, -alquilo C1-4, y -alquil-(C0-4)RAr; RY se selecciona del grupo formado por H, -alquilo C1-4, -alquil-(C0-4)RAr y -alquil-(C0-4)RAr', cada uno sustituido en forma opcional con 1, 2 ó 3 sustituyentes RN; RZ se selecciona del grupo formado por RY, -alquil-(C2-4)ORY, - alquil-(C1-2)CO2RY, -alquil-(C1-2)C(O)NRSRS' y -alquil-(C2-4)NRSRS'; cuando RY y RZ están unidos a un elemento nitrógeno, RY y RZ se seleccionan como se definió con anterioridad, o RY y RZ se toman junto con el elemento nitrógeno unido a RY y RZ para formar un anillo heterocíclico de 4-7 miembros HetRd que tiene 0 ó 1 elementos heteroatómicos adicionales seleccionados del grupo formado por O, S, y >NRM, teniendo dicho anillo heterocíclico de 4-7 miembros HetRd 0 ó 1 miembro carbonilo, y teniendo dicho anillo heterocíclico de 4-7 miembros HetRd 0 ó 1 elementos carbono de valencia permitida sustituidos por lo menos con uno de RM, -CO2H, y -alquil-(C0-1)ORY; RAr es un resto con un punto de unión en el miembro de carbono y dicho resto se selecciona del grupo formado por fenilo, piridilo, pirimidilo, y pirazinilo, donde cada elemento carbono de valencia permitida en cada uno de dichos restos está sustituido en forma independiente por lo menos con uno de 0, 1, 2 ó 3 RN, y 0 ó 1 RL; RAr' es un anillo de 3-8 miembros, que tiene 0, 1 ó 2 elementos heteroatómicos seleccionados del grupo formado por O, S, N y >NRY, que tiene 0, 1, ó 2 enlaces insaturados, que tiene 0 ó 1miembro carbonilo, donde cada elemento de valencia permitida en cada uno de dicho anillos está sustituido en forma independiente con 0, 1, ó 2 RK; y Rf es un resto hidrocarbonado lineal de
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49071003P | 2003-07-28 | 2003-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045729A1 true AR045729A1 (es) | 2005-11-09 |
Family
ID=34115427
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102683A AR045730A1 (es) | 2003-07-28 | 2004-07-28 | Moduladores de lta4h |
| ARP040102682A AR045729A1 (es) | 2003-07-28 | 2004-07-28 | Moduladores de lta4h |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102683A AR045730A1 (es) | 2003-07-28 | 2004-07-28 | Moduladores de lta4h |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20050043379A1 (es) |
| EP (2) | EP1660491B1 (es) |
| JP (2) | JP4726238B2 (es) |
| KR (2) | KR101149379B1 (es) |
| CN (2) | CN1856490A (es) |
| AR (2) | AR045730A1 (es) |
| AT (2) | ATE405562T1 (es) |
| AU (2) | AU2004261610B2 (es) |
| BR (2) | BRPI0413072A (es) |
| CA (2) | CA2534228A1 (es) |
| CY (1) | CY1108560T1 (es) |
| DE (2) | DE602004016002D1 (es) |
| DK (2) | DK1660492T3 (es) |
| ES (2) | ES2311858T3 (es) |
| HK (2) | HK1092790A1 (es) |
| HR (2) | HRP20060041B1 (es) |
| IL (1) | IL173372A (es) |
| MY (1) | MY145080A (es) |
| NO (2) | NO20060771L (es) |
| NZ (2) | NZ544970A (es) |
| PL (2) | PL1660492T3 (es) |
| PT (2) | PT1660491E (es) |
| RU (2) | RU2373204C2 (es) |
| SG (2) | SG129449A1 (es) |
| SI (2) | SI1660492T1 (es) |
| TW (2) | TWI362383B (es) |
| UA (2) | UA82888C2 (es) |
| WO (2) | WO2005012296A1 (es) |
| ZA (2) | ZA200601720B (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101149379B1 (ko) * | 2003-07-28 | 2012-06-28 | 얀센 파마슈티카 엔.브이. | 벤즈이미다졸, 벤즈티아졸 및 벤즈옥사졸 유도체 및ｌｔａ4 ｈ 조정자로서의 그의 용도 |
| CN101189012A (zh) * | 2005-03-31 | 2008-05-28 | 詹森药业有限公司 | 苯基和吡啶基lta4h调节剂 |
| ME01541B (me) | 2005-04-13 | 2014-04-20 | Astex Therapeutics Ltd | DERIVATI HIDROKSIBENZAMIDA l NJIHOVA PRIMJENA KAO INHIBITORA HSP90 |
| EP1717235A3 (en) * | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
| ATE497959T1 (de) * | 2005-09-02 | 2011-02-15 | Hoffmann La Roche | Benzoxazol-, oxazolopyridin-, benzothiazol- und thiazolopyridinderivate |
| NZ566788A (en) * | 2005-09-21 | 2012-10-26 | Decode Genetics Ehf | Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation |
| US7576102B2 (en) | 2005-12-21 | 2009-08-18 | Decode Genetics Ehf | Biaryl substituted nitrogen containing heterocycle inhibitors of LTA4H for treating inflammation |
| EP1968961A2 (en) * | 2005-12-21 | 2008-09-17 | Decode Genetics EHF | Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation |
| AU2006327243A1 (en) | 2005-12-21 | 2007-06-28 | Decode Genetics Ehf | N-linked aryl heteroaryl inhibitors of LTA4H for treating inflammation |
| ES2614090T3 (es) * | 2005-12-29 | 2017-05-29 | Celtaxsys, Inc. | Derivados de diamina como inhibidores de leucotrieno A4 hidrolasa |
| US8354434B2 (en) * | 2006-01-30 | 2013-01-15 | Purdue Pharma L.P. | Cyclourea compounds as calcium channel blockers |
| US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| US7951829B2 (en) * | 2006-05-03 | 2011-05-31 | Janssen Pharmaceutica Nv | Benzimidazole modulators of VR1 |
| WO2007144006A1 (en) * | 2006-06-16 | 2007-12-21 | H. Lundbeck A/S | Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
| US7989480B2 (en) * | 2006-08-04 | 2011-08-02 | Decode Genetics Ehf | Aryl amino acid derivatives as inhibitors for treating inflammation |
| US8115005B2 (en) | 2006-08-04 | 2012-02-14 | Decode Genetics Ehf. | Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation |
| WO2008019284A1 (en) * | 2006-08-04 | 2008-02-14 | Decode Genetics Ehf | Phenoxymethylalkyne inhibitors of lta4h for treating inflammation |
| WO2008044029A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| EP2073807A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5518478B2 (ja) | 2006-10-12 | 2014-06-11 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| TW200906396A (en) * | 2007-02-14 | 2009-02-16 | Janssen Pharmaceutica Nv | LTA4H modulators and uses thereof |
| DE602008002733D1 (de) * | 2007-03-08 | 2010-11-04 | Irm Llc | Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität |
| JPWO2008120710A1 (ja) * | 2007-03-30 | 2010-07-15 | パナソニック電工株式会社 | 活動強度計 |
| PA8802501A1 (es) * | 2007-10-31 | 2009-06-23 | Janssen Pharmaceutica Nv | Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno, hidrolasa |
| NZ585085A (en) * | 2007-11-16 | 2012-08-31 | Abbott Lab | Method of treating arthritis using arylsulfonamide compounds |
| GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| WO2009126806A2 (en) * | 2008-04-11 | 2009-10-15 | Janssen Pharmaceutica Nv | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase |
| PT2294066E (pt) | 2008-04-28 | 2014-11-21 | Janssen Pharmaceutica Nv | Benzoimidazoles como inibidores da prolil-hidroxilase |
| EP2430019B1 (en) * | 2009-05-14 | 2013-09-18 | Janssen Pharmaceutica, N.V. | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase |
| CN102442961A (zh) * | 2010-11-10 | 2012-05-09 | 江苏德峰药业有限公司 | 1-甲基四氮唑的生产方法 |
| CN102442962A (zh) * | 2010-11-10 | 2012-05-09 | 江苏德峰药业有限公司 | 1-烷基四氮唑的生产方法 |
| BR112014009910B1 (pt) | 2011-10-25 | 2020-06-30 | Janssen Pharmaceutica N.V. | sal di-hidrato de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico, composição farmacêuticae pomada tópica |
| AU2014249168B2 (en) | 2013-03-12 | 2018-07-12 | Celltaxis, Llc | Methods of inhibiting leukotriene A4 hydrolase |
| RU2678196C2 (ru) | 2013-03-14 | 2019-01-24 | Селтакссис, Инк. | Производные 2-фениламино-3-цианопиразоло[1,5-а]пиримидина, полезные в качестве ингибитора лейкотриен-a4-гидролазы |
| MX2015011677A (es) | 2013-03-14 | 2016-07-08 | Celtaxsys Inc | Inhibidores de leucotrieno a4 hidrolasa. |
| BR112015022227A2 (pt) * | 2013-03-14 | 2017-07-18 | Celtaxsys Inc | inibidores de leucotrieno a4 hidrolase |
| JP6212644B2 (ja) * | 2013-12-17 | 2017-10-11 | イーライ リリー アンド カンパニー | フェノキシエチル環状アミン誘導体およびｅｐ４受容体モジュレーターとしてのその活性 |
| WO2016100823A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute, Inc. | Dopamine d2 receptor ligands |
| EP3233077A4 (en) | 2014-12-19 | 2018-08-08 | The Broad Institute Inc. | Dopamine d2 receptor ligands |
| LT3307734T (lt) | 2015-06-09 | 2020-05-11 | Abbvie Inc. | Branduolinio receptoriaus moduliatoriai (ror), skirti uždegiminių ir autoimuninių ligų gydymui |
| EP3559249A1 (en) | 2016-12-21 | 2019-10-30 | H. Hoffnabb-La Roche Ag | Method for in vitro glycoengineering of antibodies |
| CN107663192B (zh) * | 2017-11-03 | 2019-05-10 | 梯尔希（南京）药物研发有限公司 | 一种雷贝拉唑杂质的制备方法 |
| EP3801559A4 (en) | 2018-05-31 | 2022-03-02 | Celltaxis, LLC | METHOD FOR REDUCING LUNG EXACERBATIONS IN PATIENTS SUFFERING FROM RESPIRATORY DISEASE |
| EP3908278A4 (en) * | 2019-01-11 | 2022-09-28 | Naegis Pharmaceuticals Inc. | LEUCOTRIENE SYNTHESIS INHIBITORS |
| CN110026557B (zh) * | 2019-05-28 | 2021-08-27 | 南方科技大学 | 一种混合固体颗粒重熔的直写装置及成型方法 |
| CR20230258A (es) * | 2020-11-19 | 2023-09-12 | Telo Therapeutics Inc | Compuestos y composiciones de moléculas pequeñas |
| CN113683491A (zh) * | 2021-09-01 | 2021-11-23 | 王传良 | 一种4-(2-溴乙基)苯酚的制备方法 |
| CN113735798B (zh) * | 2021-09-27 | 2022-07-12 | 安徽美致诚药业有限公司 | 一种盐酸罗沙替丁醋酸酯的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873346A (en) | 1985-09-20 | 1989-10-10 | The Upjohn Company | Substituted benzothiazoles, benzimidazoles, and benzoxazoles |
| CA1319144C (en) * | 1986-11-14 | 1993-06-15 | Quirico Branca | Tetrahydronaphthalene derivatives |
| IT1240598B (it) * | 1990-03-13 | 1993-12-17 | Mini Ricerca Scient Tecnolog | Derivati amminici ad azione antifungina |
| US5585492A (en) * | 1994-10-11 | 1996-12-17 | G. D. Searle & Co. | LTA4 Hydrolase inhibitors |
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| US5925654A (en) * | 1997-03-12 | 1999-07-20 | G.D. Searle & Co. | LTA4 , hydrolase inhibitors |
| ID26123A (id) * | 1998-02-25 | 2000-11-23 | Genetics Inst | Penghambat-penghambat phospholipase a2 |
| US6514964B1 (en) * | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
| US20040110757A1 (en) * | 2002-03-21 | 2004-06-10 | Thomas Arrhenius | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis |
| KR101149379B1 (ko) * | 2003-07-28 | 2012-06-28 | 얀센 파마슈티카 엔.브이. | 벤즈이미다졸, 벤즈티아졸 및 벤즈옥사졸 유도체 및ｌｔａ4 ｈ 조정자로서의 그의 용도 |
| US7541466B2 (en) * | 2003-12-23 | 2009-06-02 | Genzyme Corporation | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases |
| MX2007011273A (es) * | 2005-03-16 | 2007-11-08 | Meda Pharma Gmbh & Co Kg | La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias. |
| TW200906396A (en) * | 2007-02-14 | 2009-02-16 | Janssen Pharmaceutica Nv | LTA4H modulators and uses thereof |
-
2004
- 2004-07-27 KR KR1020067002194A patent/KR101149379B1/ko not_active IP Right Cessation
- 2004-07-27 CA CA002534228A patent/CA2534228A1/en not_active Abandoned
- 2004-07-27 UA UAA200601432A patent/UA82888C2/uk unknown
- 2004-07-27 KR KR1020067002211A patent/KR20060054408A/ko not_active Application Discontinuation
- 2004-07-27 US US10/900,152 patent/US20050043379A1/en not_active Abandoned
- 2004-07-27 BR BRPI0413072-3A patent/BRPI0413072A/pt not_active IP Right Cessation
- 2004-07-27 ES ES04779219T patent/ES2311858T3/es active Active
- 2004-07-27 DE DE602004016002T patent/DE602004016002D1/de active Active
- 2004-07-27 WO PCT/US2004/024050 patent/WO2005012296A1/en active Application Filing
- 2004-07-27 RU RU2006102510/04A patent/RU2373204C2/ru not_active IP Right Cessation
- 2004-07-27 ES ES04779375T patent/ES2313079T3/es active Active
- 2004-07-27 CN CNA2004800279067A patent/CN1856490A/zh active Pending
- 2004-07-27 SG SG200700691A patent/SG129449A1/en unknown
- 2004-07-27 CA CA002534212A patent/CA2534212A1/en not_active Abandoned
- 2004-07-27 SI SI200430927T patent/SI1660492T1/sl unknown
- 2004-07-27 AT AT04779375T patent/ATE405562T1/de active
- 2004-07-27 PL PL04779375T patent/PL1660492T3/pl unknown
- 2004-07-27 JP JP2006522022A patent/JP4726238B2/ja not_active Expired - Fee Related
- 2004-07-27 CN CN200480028138A patent/CN100591679C/zh not_active Expired - Fee Related
- 2004-07-27 AU AU2004261610A patent/AU2004261610B2/en not_active Ceased
- 2004-07-27 AU AU2004261628A patent/AU2004261628B2/en not_active Ceased
- 2004-07-27 US US10/900,103 patent/US20050043378A1/en not_active Abandoned
- 2004-07-27 SG SG200700817-0A patent/SG130192A1/en unknown
- 2004-07-27 WO PCT/US2004/024309 patent/WO2005012297A1/en active Application Filing
- 2004-07-27 DK DK04779375T patent/DK1660492T3/da active
- 2004-07-27 EP EP04779219A patent/EP1660491B1/en not_active Not-in-force
- 2004-07-27 AT AT04779219T patent/ATE403654T1/de not_active IP Right Cessation
- 2004-07-27 JP JP2006521973A patent/JP2007500703A/ja active Pending
- 2004-07-27 SI SI200430904T patent/SI1660491T1/sl unknown
- 2004-07-27 NZ NZ544970A patent/NZ544970A/en unknown
- 2004-07-27 PT PT04779219T patent/PT1660491E/pt unknown
- 2004-07-27 UA UAA200601433A patent/UA87986C2/uk unknown
- 2004-07-27 BR BRPI0412345-0A patent/BRPI0412345A/pt not_active IP Right Cessation
- 2004-07-27 DE DE602004015620T patent/DE602004015620D1/de active Active
- 2004-07-27 NZ NZ544938A patent/NZ544938A/en unknown
- 2004-07-27 PT PT04779375T patent/PT1660492E/pt unknown
- 2004-07-27 DK DK04779219T patent/DK1660491T3/da active
- 2004-07-27 EP EP04779375A patent/EP1660492B1/en not_active Not-in-force
- 2004-07-27 PL PL04779219T patent/PL1660491T3/pl unknown
- 2004-07-27 RU RU2006102508/04A patent/RU2359970C2/ru not_active IP Right Cessation
- 2004-07-28 MY MYPI20043045A patent/MY145080A/en unknown
- 2004-07-28 TW TW093122570A patent/TWI362383B/zh not_active IP Right Cessation
- 2004-07-28 AR ARP040102683A patent/AR045730A1/es not_active Application Discontinuation
- 2004-07-28 TW TW093122566A patent/TW200520756A/zh unknown
- 2004-07-28 AR ARP040102682A patent/AR045729A1/es unknown
-
2006
- 2006-01-26 IL IL173372A patent/IL173372A/en not_active IP Right Cessation
- 2006-01-27 HR HRP20060041AA patent/HRP20060041B1/hr not_active IP Right Cessation
- 2006-01-27 HR HR20060039A patent/HRP20060039A2/xx not_active Application Discontinuation
- 2006-02-17 NO NO20060771A patent/NO20060771L/no not_active Application Discontinuation
- 2006-02-20 NO NO20060823A patent/NO20060823L/no not_active Application Discontinuation
- 2006-02-27 ZA ZA200601720A patent/ZA200601720B/en unknown
- 2006-02-27 ZA ZA200601716A patent/ZA200601716B/en unknown
- 2006-09-21 HK HK06110546.2A patent/HK1092790A1/xx not_active IP Right Cessation
- 2006-09-28 HK HK06110816A patent/HK1090359A1/xx not_active IP Right Cessation
-
2008
- 2008-10-27 CY CY20081101220T patent/CY1108560T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045729A1 (es) | Moduladores de lta4h | |
| RS52937B (en) | SULFONYLPYROLS AS HDAC INHIBITORS | |
| AR019626A1 (es) | Antagonistas receptores y5 de neuropeptidos. | |
| AR065355A1 (es) | Moduladores de lta4h y sus usos | |
| AR045930A1 (es) | Compuestos de quinoxalina | |
| RS53052B (en) | INHIBITOR BETA-LACTAMASE | |
| CO5690642A2 (es) | Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibi- dores de fosfodiesterasa | |
| AR025386A1 (es) | Moduladores de los receptores activados del proliferador de peroxisomas | |
| AR040346A2 (es) | Compuestos intermediarios para la sintesis de benzamido-piperidinas | |
| WO2007075629A3 (en) | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists | |
| PE20020753A1 (es) | Heteroaromaticos fusionados como activadores de la glucoquinasa | |
| AR049443A1 (es) | Derivados de pirrolpiridinas | |
| WO2008063609A3 (en) | Diimide-based semiconductor materials and methods of preparing and using the same | |
| HRP20110621T1 (en) | Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors | |
| ATE204269T1 (de) | Substituierte biphenyl- oder phenylpyridinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen | |
| CO5690577A2 (es) | Derivados de imidazoquinolina como ligandos receptores de adenosina a3 | |
| ATE521606T1 (de) | Quaternäre ammoniumsalze als m3-antagonisten | |
| CR9822A (es) | Derivados de benzotiazol ciclobutil amina y su uso como ligandos de los receptores 3 de histamina | |
| DOP2010000226A (es) | Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos | |
| AR049121A1 (es) | Compuestos quimicos que contienen anillos de oxazolidinona e isoxazolina sustituida | |
| WO2006074192A3 (en) | Treatment of inflammatory disorders | |
| PH12020500408A1 (en) | Cycloolefin substituted heteroaromatic compounds and their use | |
| AR056418A1 (es) | Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento | |
| AR045326A1 (es) | Derivados de aminoquinolina y su uso como ligandos a3 de adenosina | |
| AR103444A1 (es) | Forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |